Journal: Acta Obstetricia et Gynecologica Scandinavica

Article Title: A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

doi: 10.1111/aogs.15020

Figure Lengend Snippet: Targeted antigens and antibodies used for the EV Array Analysis. References are provided only for non‐commercial antibodies.

Article Snippet: The detection of Total EVs was conducted with biotinylated anti‐human antibodies to CD9, CD63, and CD81 (LifeSpan BioSciences, Lynnwood, WA, USA).

Techniques: Membrane, Coagulation

Journal: Acta Obstetricia et Gynecologica Scandinavica

Article Title: A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

doi: 10.1111/aogs.15020

Figure Lengend Snippet: Principle of analysis of the extracellular vesicle (EV) Array. A customized antibody microarray is generated onto glass slides. EVs from unprocessed plasma or UC enriched EVs are added and EVs are captured during incubation. Step 2 is either performed using a cocktail of anti‐CD9, CD63 and CD81 to detect the total amount of EVs or by using anti‐PP13 to detect only placenta‐derived EVs. After Step 2 fluorescent streptavidin is added prior to scanning.

Article Snippet: The detection of Total EVs was conducted with biotinylated anti‐human antibodies to CD9, CD63, and CD81 (LifeSpan BioSciences, Lynnwood, WA, USA).

Techniques: Microarray, Generated, Incubation, Derivative Assay

Journal: Acta Obstetricia et Gynecologica Scandinavica

Article Title: A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

doi: 10.1111/aogs.15020

Figure Lengend Snippet: Heatmap with an overview of the extracellular vesicle (EV) characteristics obtained by EV Array analysis directly on plasma. The results are calculated as log2 transformed relative intensities. Left side: Data obtained by detection using anti‐CD9, CD63 and CD81 antibodies to characterize the total plasma content of EVs. Right side: Data obtained by detection using anti‐PP13 antibodies to characterize the placental‐derived EV.

Article Snippet: The detection of Total EVs was conducted with biotinylated anti‐human antibodies to CD9, CD63, and CD81 (LifeSpan BioSciences, Lynnwood, WA, USA).

Techniques: Transformation Assay, Derivative Assay

Journal: Acta Obstetricia et Gynecologica Scandinavica

Article Title: A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

doi: 10.1111/aogs.15020

Figure Lengend Snippet: Comparing results from raw plasma extracellular vesicles (EVs) vs ultracentrifuged pelleted enriched EVs. Green dots to the right 3 columns indicate detection of total EVs using antibodies to CD9, CD63 and CD81 as specific tetraspanins markers of EVs. Red dots at the right three columns marks the placental‐derived EVs detected by anti‐PP13 antibodies. The couple of samples plotted in each shows the signal obtained from the raw plasma preparation vs the pelleted EV sample indicating the reliability and accuracy of the direct plasma samples overlay on the surface of the glass slide of the EV Array.

Article Snippet: The detection of Total EVs was conducted with biotinylated anti‐human antibodies to CD9, CD63, and CD81 (LifeSpan BioSciences, Lynnwood, WA, USA).

Techniques: Derivative Assay

Journal: Acta Obstetricia et Gynecologica Scandinavica

Article Title: A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

doi: 10.1111/aogs.15020

Figure Lengend Snippet: Performance of total EVs vs placental EV markers in predicting pregnancy complications.

Article Snippet: The detection of Total EVs was conducted with biotinylated anti‐human antibodies to CD9, CD63, and CD81 (LifeSpan BioSciences, Lynnwood, WA, USA).

Techniques: